Skip to content

Algen Biotechnologies

YC W20 · Active · Using CRISPR to find treatments for cancer and inflammation

Competitors

Adjacent

Also from W20 in AI

All of W20

About Algen Biotechnologies

Algen is using CRISPR to uncover disease-driving RNA messages to find treatments for cancer, inflammation and diseases with high unmet needs. We are harnessing the power of CRISPR and machine learning to find first-in-class drugs that modulate RNA messages at single-cell resolution. Algen's founders are bioengineer from Jennifer Doudna Lab and biotech commercialization expert, teamed up with experienced pharmaceutical executives.

YC batch
W20 · Winter 2020
Status, per YC
Active
Category
AI
Team size
15
Location
San Francisco, CA, USA
Checked
1h ago

YC tags: CRISPR, Biotech, Therapeutics, Drug discovery, AI

Algen Biotechnologies in W20: 228 companies, 29% AI

Algen Biotechnologies: questions

Which YC batch was Algen Biotechnologies in?

Algen Biotechnologies was in Y Combinator's Winter 2020 batch (W20).

Is Algen Biotechnologies still active?

Y Combinator lists Algen Biotechnologies as active.

Where is Algen Biotechnologies based?

Algen Biotechnologies lists San Francisco, CA, USA as its location on YC's directory.

Sources: each program's public company list, read twice a week. Not affiliated with Y Combinator or any other program. Logos via logo.dev; trademarks belong to their owners.

New startups by email

Mondays: new YC data, AI and devtools companies and status changes, only when something changed.

Double opt-in. Unsubscribe any time.